Coverage Initiated on Developer of Psychedelic Drugs for PTSD Smoking Cessation

The investment thesis for Mydecine Innovations Group is presented in a ROTH Capital Partners report. In a June 22 research note, analyst Elemer Piros reported that ROTH Capital Partners initiated coverage on Mydecine Innovations Group Inc. (MYCO:NEO; MYCOF:OTCMKTS; 0NFA:FSE) with a Buy rating and a CA$3 per share target price. Its current share price is about CA$0.38. Piros explained the rationale behind ROTH’s Buy recommendation on Mydecine, formerly named NewLeaf Brands. First, the concept and objectives Mydecine is pursuing are innovative and, thus, differentiate it from other biopharmaceutical firms, Piros highlighted. This Vancouver-based company is developing alternative medicines based on…

Coverage Initiated on Developer of Psychedelic Drugs for PTSD Smoking Cessation Topshelf News.

source https://topshelf.news/coverage-initiated-on-developer-of-psychedelic-drugs-for-ptsd-smoking-cessation/